Inhalants finally have a regulatory moment — and the recovery field isn’t ready

The substance most likely to be sitting in an American kitchen drawer right now is also the one almost nobody wants to talk about.

Whipped-cream chargers. Office-supply duster cans. Markers. Glue. The eight-gram nitrous oxide cartridges that flew off shelves at gas stations under brand names like Galaxy Gas. For thirty years, inhalants have been the hardest substance class to regulate — partly because most of the products have legitimate uses, partly because the people most affected are too young to vote, and partly because the field’s attention has, understandably, been pulled toward fentanyl.

That is starting to change. And it’s worth paying attention now, because the regulatory moves arriving this year are happening faster than the treatment infrastructure that should follow them.

What’s actually new

On January 1, 2026, Oregon HB 3447 took effect, requiring sellers to verify that buyers are at least 18 before completing a sale of nitrous oxide. Florida already prohibits single-purchase quantities of nitrous oxide above 16 grams, and a new bill in this year’s session is moving to expand that. Class-action and wrongful-death cases against Galaxy Gas and several retailers are advancing through court, and the FDA’s March 2025 consumer warning on recreational nitrous use is still live and being cited by plaintiffs’ counsel.

What you don’t see in the federal record is anything close to comprehensive. There is no FDA certification for the recreational-grade product, no purity testing, no canister size limit, no import controls for the cheaper variants now arriving from overseas, and no standardization across states. The patchwork is real — and it’s also why this moment is so awkward for clinicians and families. A drug that’s restricted in Salem may be sold in volume two hundred miles away in Boise.

Why the data has been hiding

In 2023, less than 1% of Americans aged 12 and older reported past-year inhalant use, according to the National Survey on Drug Use and Health. That figure is the one most often cited, and it is the one that has kept inhalants off most state and federal addiction agendas for two decades.

The number that should be cited alongside it: roughly 4% of US 8th graders — about 14-year-olds — reported past-year inhalant use in the NIDA-funded Monitoring the Future survey. Inhalants are the only substance class in the survey where younger adolescents use at higher rates than older adolescents and adults. The familiar adult prevalence number, by hiding the age skew, has under-counted the impact for years.

NIDA estimates inhalants are deadly for 100 to 200 youths in the United States each year. “Sudden sniffing death” — a fatal cardiac arrhythmia triggered by a single inhalation — is most often the mechanism, and it can happen on a first use. The non-fatal harms are also distinct: peripheral neuropathies and limb spasms from chronic nitrous oxide exposure are now showing up in emergency departments at rates the field is not yet tracking systematically.

Why the treatment system is behind

Most adult-focused outpatient programs do not have an inhalant-specific clinical pathway. Residential programs that serve adolescents may screen for inhalant use, but the treatment matching is approximate — most clinicians end up adapting protocols designed for other substances, because there are very few peer-reviewed inhalant-specific protocols to adapt from. The Cochrane review database, which provides systematic reviews for almost every other substance class, is conspicuously thin here.

This is a coverage problem the regulatory wave is about to expose. As state laws come online, primary care physicians and ER attendings will be asked to make a referral. The referral that exists today is either to a generalist outpatient program or to a youth residential program. Neither was designed for the specific neurological, psychiatric, and family-systems profile of inhalant use disorder.

The referral that exists today is either to a generalist outpatient program or to a youth residential program.

What families need to know right now

If you’re a parent, a caregiver, or a young person reading this: the most useful thing you can do this week is have a calm, factual conversation. Inhalant use among adolescents is meaningfully more associated with secrecy and isolation than other substance classes, in part because the products are so accessible and so easy to use without anyone noticing. Conversation, not surveillance, is what the research supports.

If you’re a clinician: this is a good week to refresh your screening. The CRAFFT and S2BI tools both ask about inhalants; many clinicians skip the question because they assume the prevalence is low. The age-stratified data says don’t.

If you’re a treatment program director: building an inhalant-specific track is going to be harder than building one for fentanyl, because the evidence base is so much thinner. But the regulatory moment is going to bring referrals you don’t currently know how to handle. The infrastructure question is now.

Why this matters for people in recovery

Recovery isn’t only about the substances we’ve been told to take seriously. It’s about every substance that is hurting someone — and that includes the ones in cans of duster spray and behind the counter at a corner store. The recovery field has spent the last five years building incredible expertise in opioid pharmacotherapy. That expertise does not transfer cleanly to inhalants.

For adults in recovery from another substance who notice a young person in their life using inhalants: trust that instinct. The numbers say the household is more likely to be the place where this gets caught early. And the people who navigate recovery systems already know how to make a phone call without panic. That skill matters here.

If you or someone you love is struggling with inhalant use, Rize Recovery’s resource directory can help you locate adolescent-trained programs in your area. Confidential. Free. Not a clinical service.

If you are in immediate crisis, call 988.

---

Coverage notes: This piece is informational and is not a substitute for clinical advice. Sources cited above are linked inline. We will update this article as Florida and additional state bills move through their 2026 sessions.